Memphasys Secures AU$800,000 Capital Raise to Accelerate Felix™ Commercialisation
Memphasys Limited (ASX: MEM) has raised AU$800,000 through a share placement, issuing 160 million shares at AU$0.005 per share, representing a 28.6% discount to the last closing price. The capital raise was met with significant interest from both existing and new institutional investors, alongside sophisticated investors. Proceeds from the placement will be used to accelerate the commercialisation of Memphasys' flagship product, Felix™, which has already secured CE Mark approval. Funds will support scaling the direct selling model, advancing regulatory approvals, and increasing manufacturing capacity to meet growing customer demand. With initial revenue invoicing already underway across multiple international markets and further regulatory submissions lodged in Australia and India, the funding will allow Memphasys to strengthen its position in the assisted reproductive technology (ART) market. The placement shares are anticipated to be allocated by 16 February 2026.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au
x
Daily Dose of Buy, Sell & Hold recommendations before the market opens.
Start Your 7 Days Free Trial Now!
We use cookies to help us improve, promote, and protect our services.
By continuing to use this site, we assume you consent to this.
Read our
Privacy Policy
and
Terms & Conditions
Memphasys Secures AU$800,000 Capital Raise to Accelerate Felix™ Commercialisation
Memphasys Limited (ASX: MEM) has raised AU$800,000 through a share placement, issuing 160 million shares at AU$0.005 per share, representing a 28.6% discount to the last closing price. The capital raise was met with significant interest from both existing and new institutional investors, alongside sophisticated investors. Proceeds from the placement will be used to accelerate the commercialisation of Memphasys' flagship product, Felix™, which has already secured CE Mark approval. Funds will support scaling the direct selling model, advancing regulatory approvals, and increasing manufacturing capacity to meet growing customer demand. With initial revenue invoicing already underway across multiple international markets and further regulatory submissions lodged in Australia and India, the funding will allow Memphasys to strengthen its position in the assisted reproductive technology (ART) market. The placement shares are anticipated to be allocated by 16 February 2026.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au